Dublin, April 06, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" to their offering.
Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.
The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.
The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2015, projections are made to the years 2020 and 2025.
The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.
Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 80 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report. The report is supplemented with 52 tables and 12 figures.
Key Topics Covered:
Executive Summary
1. Basics of Drug Delivery to the Central Nervous System
2. Blood Brain Barrier
3. Methods of Drug Delivery to the CNS
4. Delivery of Cell, Gene and Antisense Therapies to the CNS
5. Drug Delivery for Treatment of Neurological Disorders
6. Drug delivery for brain tumors
7. Markets for Drug Delivery in CNS Disorders
8. Companies
9. References
For more information visit http://www.researchandmarkets.com/research/xd39mp/drug_delivery_in
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Delivery


Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S.
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 



